An official website of the European Union How do you know?      
European Commission logo
JRC Publications Repository Menu

225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts

cover
Although a lot of progress has been made in the treatment of clear cell renal cell carcinoma (ccRCC), the prognosis of patients with metastasized tumors remains poor. Therefore, novel treatment options need to be developed. A rapidly advancing field of interest is targeted radionuclide therapy using α-emitting radionuclides, such as actinium-225 (225Ac). Carbonic anhydrase IX (CAIX) is over expressed in ccRCC and can be targeted effectively using the monoclonal antibody girentuximab. The aim of this preclinical study was to radiolabel girentuximab with actinium-225 and assess its in vivo tumor targeting properties, therapeutic efficacy and toxicity in mice.
2019-07-24
ELSEVIER BV
JRC116486
1939-8654 (online),   
https://publications.jrc.ec.europa.eu/repository/handle/JRC116486,   
10.1016/j.jmir.2019.03.079 (online),   
Language Citation
NameCountryCityType
Datasets
IDTitlePublic URL
Dataset collections
IDAcronymTitlePublic URL
Scripts / source codes
DescriptionPublic URL
Additional supporting files
File nameDescriptionFile type 
Show metadata record  Copy citation url to clipboard  Download BibTeX
Items published in the JRC Publications Repository are protected by copyright, with all rights reserved, unless otherwise indicated. Additional information: https://ec.europa.eu/info/legal-notice_en#copyright-notice